Ignite Creation Date:
2025-12-26 @ 10:46 PM
Ignite Modification Date:
2025-12-26 @ 10:46 PM
Study NCT ID:
NCT04051112
Status:
COMPLETED
Last Update Posted:
2022-05-06
First Post:
2019-08-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites
Sponsor:
Sichuan Clover Biopharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-09-28
Start Date Type:
ACTUAL
Primary Completion Date:
2021-12-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-04-21
Completion Date Type:
ACTUAL
First Submit Date:
2019-08-04
First Submit QC Date:
None
Study First Post Date:
2019-08-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-05-05
Last Update Post Date:
2022-05-06
Last Update Post Date Type:
ACTUAL